- Prof. Ting-Chang Chang
- Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital, Taoyuan, Taiwan, China.
Website | E-mail
Special Issue Introduction
Although surgery is the primary step in treating patients with gynecologic cancer, adjuvant therapy is a critical measure to consolidate surgical effect and prevent a recurrence especially for advance-staged diseases. Adjuvant therapies and its effects have been tested and well confirmed in randomized clinical trials and put into treatment guidelines for reference. Nevertheless, discoveries in the disease nature and novel therapeutic agents provide opportunity to modify treatment policy for better outcome in terms of prolonged survival and satisfied life quality.
There is a big jump in survival outcome of advanced epithelial ovarian cancer after the introduction of paclitaxel in 1990's, along with the effort to achieve optimal debulking, i.e., reducing the residual tumor volume at surgery. Survival of such patients extended, from 24 months starting from diagnosis before paclitaxel to 37 months after paclitaxel. Following this jump, there was a silent period and minor improvements continued until most recent.
In recent years, concept of precision medicine has been growing in the field of gynecologic cancer. Molecular tumor profiling and large databases such as TCGA and NCI-Match have provided us with large amounts of molecular data and clinical application. Novel therapeutic agents, that capitalize on genetic and immune discoveries provides new opportunities for promoting treatment outcome. The combination of standard treatment and novel therapy, including VEGF inhibitors, PARP inhibitors, and immune check point blockage, often shows better treatment outcomes. New regimens for gynecologic cancer are proposed and being tested through international collaboration. All professionals participating in research and treatment of gynecologic cancer face a period of prosperity and own the turn point to change the world in this era. At this point, "Current Treatment Strategies for Gynecologic Cancer" in this issue provides us with a wonderful place to keep our records and share with our colleagues.
Submission Deadline31 Dec 2020